Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASH 2019
Biotech
Sanofi eyes FDA filing as orphan blood drug hits late-phase goal
More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.
Nick Paul Taylor
Dec 10, 2019 7:30am
Bluebird's CAR-T follow-up shows promise in phase 1
Dec 9, 2019 6:15pm
Merck inks $2.7B ArQule deal, teeing up cancer race with Lilly
Dec 9, 2019 10:25am
ASH: Amgen's BiTE stalls multiple myeloma relapse in mice
Dec 9, 2019 8:45am
Lilly plots 'ambitious' cancer program after sharing early data
Dec 8, 2019 4:30pm
J&J's CAR-T clears multiple myeloma in 69% of patients
Dec 7, 2019 5:38pm
